168 related articles for article (PubMed ID: 37727078)
1. Modelling three-dimensional cancer-associated cachexia and therapy: The molecular basis and therapeutic potential of interleukin-6 transignalling blockade.
Cosentino M; Forcina L; Zouhair M; Apa L; Genovese D; Boccia C; Rizzuto E; Musarò A
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2550-2568. PubMed ID: 37727078
[TBL] [Abstract][Full Text] [Related]
2. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.
Seto DN; Kandarian SC; Jackman RW
J Biol Chem; 2015 Aug; 290(32):19976-86. PubMed ID: 26092726
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
4. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
6. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
[TBL] [Abstract][Full Text] [Related]
8. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia.
Judge SM; Wu CL; Beharry AW; Roberts BM; Ferreira LF; Kandarian SC; Judge AR
BMC Cancer; 2014 Dec; 14():997. PubMed ID: 25539728
[TBL] [Abstract][Full Text] [Related]
10. Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles.
Fan M; Gu X; Zhang W; Shen Q; Zhang R; Fang Q; Wang Y; Guo X; Zhang X; Liu X
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2724-2739. PubMed ID: 36085573
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
12. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
13. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.
Chiappalupi S; Sorci G; Vukasinovic A; Salvadori L; Sagheddu R; Coletti D; Renga G; Romani L; Donato R; Riuzzi F
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):929-946. PubMed ID: 32159297
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle.
Hardee JP; Counts BR; Gao S; VanderVeen BN; Fix DK; Koh HJ; Carson JA
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):369-383. PubMed ID: 29215198
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
16. Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia.
Dolly A; Pötgens SA; Thibaut MM; Neyrinck AM; de Castro GS; Galbert C; Lefevre C; Wyart E; Gomes SP; Gonçalves DC; Lanthier N; Baldin P; Huot JR; Bonetto A; Seelaender M; Delzenne NM; Sokol H; Bindels LB
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1569-1582. PubMed ID: 37127348
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia.
Pototschnig I; Feiler U; Diwoky C; Vesely PW; Rauchenwald T; Paar M; Bakiri L; Pajed L; Hofer P; Kashofer K; Sukhbaatar N; Schoiswohl G; Weichhart T; Hoefler G; Bock C; Pichler M; Wagner EF; Zechner R; Schweiger M
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):93-107. PubMed ID: 36351437
[TBL] [Abstract][Full Text] [Related]
18. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
19. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.
Berardi E; Aulino P; Murfuni I; Toschi A; Padula F; Scicchitano BM; Coletti D; Adamo S
Neurol Res; 2008 Mar; 30(2):160-9. PubMed ID: 18397608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
